A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities-Reference-Cited by-同舟云学术

A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities

Published:2016-09-01 Issue:12 Volume:71 Page:3575-3584
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:J. Antimicrob. Chemother.

Author:

Dryden Matthew,Zhang Yingyuan,Wilson David,Iaconis Joseph P.,Gonzalez Jesus

Funder

AstraZeneca

Elizabeth Bolton

Mark Waterlow of Prime Medica Ltd

AstraZeneca and Actavis

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/71/12/3575/13761119/dkw333.pdf

Reference33 articles.

1. Trends in US Hospital Admissions for Skin and Soft Tissue Infections

2. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

3. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

4. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin

5. AstraZeneca AB. Zinforo 600 mg Powder for Concentrate for Solution for Infusion. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002252/WC500132586.pdf .

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of MRSA Infection: Where are We?;Current Medicinal Chemistry;2024-08

2. Real-World Use and Treatment Outcomes of Ceftaroline Fosamil in Patients with Complicated Skin and Soft Tissue Infection: A Multinational Retrospective Study;Infection and Drug Resistance;2024-07

3. Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study;JAC-Antimicrobial Resistance;2024-05-06

4. Herbal Bioactive Compounds for Skin Infections and Inflammatory Conditions;Open Access Macedonian Journal of Medical Sciences;2024-04-05

5. Antimicrobial Drug Penetration is Enhanced by Lung Tissue Inflammation and Injury;American Journal of Respiratory and Critical Care Medicine;2023-12-15